Scottsdale Health Partners helps patients with social needs through a complex care coordination program and working with community resources like adult protective services or other city government branches, James Whitfill, MD, chief medical officer, explained at the National Association of ACOs Spring 2016 Conference.
Scottsdale Health Partners helps patients with social needs through a complex care coordination program and working with community resources like adult protective services or other city government branches, James Whitfill, MD, chief medical officer, explained at the National Association of ACOs Spring 2016 Conference.
Transcript (modified)
How does the Scottsdale Health Partners ACO assist patients with social needs that could impact their health?
So I think probably 2-3 different areas that we really work to try to address a lot of those, whether you call them social determinants of health or personal barriers towards health: first of all we have a complex care coordination program that is, for the most part, staffed by medical assistants (MAs), we do have a few registered nurses in that. The MAs are pretty resourceful because they’re closer to that community, and they oftentimes are willing to think pretty unconventionally about what we need to do in order to solve a person’s issues. And so we will have 1-on-1 relationships between, say, a care coordinator and a patient.
At the same time we’re very involved in the city of Scottsdale and the community resources there, whether it’s the adult protective services, whether it’s the fire department, the paramedics—there’s oftentimes a lot of overlap between our higher risk patients and those that the community or the city government is trying to do outreach with.
Infant Mortality Increases Across US Following Dobbs Decision
October 25th 2024The Dobbs decision was associated with a 7% absolute increase in overall infant mortality—equivalent to 247 excess deaths—and a 10% increase among infants with congenital anomalies, corresponding to 204 additional deaths.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Accountable Care Organizations and HPV Vaccine Uptake: A Multilevel Analysis
October 24th 2024The authors evaluated whether adolescents receiving care at accountable care organizations (ACOs) vs non-ACOs were more likely to initiate and complete the human papillomavirus (HPV) vaccination series.
Read More
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Infant Mortality Increases Across US Following Dobbs Decision
October 25th 2024The Dobbs decision was associated with a 7% absolute increase in overall infant mortality—equivalent to 247 excess deaths—and a 10% increase among infants with congenital anomalies, corresponding to 204 additional deaths.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Accountable Care Organizations and HPV Vaccine Uptake: A Multilevel Analysis
October 24th 2024The authors evaluated whether adolescents receiving care at accountable care organizations (ACOs) vs non-ACOs were more likely to initiate and complete the human papillomavirus (HPV) vaccination series.
Read More
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
2 Commerce Drive
Cranbury, NJ 08512